SECsense Logo

AstraZeneca PLC April 2025 Financial Report: Voting Rights & Compliance Insights

$AZN
Form 6-K
Filed on: 2025-04-01
Source
AstraZeneca PLC April 2025 Financial Report: Voting Rights & Compliance Insights

Here are the key insights extracted from the financial report of AstraZeneca PLC, as presented in the SEC Form 6-K:

  1. Company Information:
  • Name: AstraZeneca PLC
  • Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom.
  • SEC Commission File Number: 001-11960.
  1. Reporting Period:
  • The report is for the month of April 2025.
  1. Total Voting Rights:
  • As of March 31, 2025, AstraZeneca's issued share capital with voting rights consists of 1,550,623,487 ordinary shares with a nominal value of US$0.25 each.
  • There are no shares held in Treasury, meaning all issued shares are available for voting.
  1. Total Voting Rights Calculation:
  • The total number of voting rights in AstraZeneca PLC is stated to be 1,550,623,487. This figure is important for shareholders as it serves as the denominator for determining whether they need to notify changes in their interest in the company under UK Financial Conduct Authority's Disclosure and Transparency Rules.
  1. Regulatory Compliance:
  • The report complies with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, emphasizing transparency in reporting voting rights.
  1. Company Overview:
  • AstraZeneca is described as a global, science-led biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines, particularly in Oncology, Rare Diseases, and BioPharmaceuticals.
  • The company operates in over 125 countries and serves millions of patients worldwide.
  1. Contact Information:
  • The Company Secretary is Adrian Kemp.
  • The report includes links for contacting the Investor Relations Team and Media contacts.
  1. Signature:
  • The report is signed by Adrian Kemp, the Company Secretary, confirming its authenticity and compliance with regulatory requirements.

This summary encapsulates the critical information from the financial report, highlighting AstraZeneca's voting rights, compliance with regulatory standards, and a brief overview of the company's operations.